OraSure Technologies Inc. 2026 Third Quarter Earnings Conference Call - ORASURE TECHNOLOGIES INC

Financial Performance:

• Total revenue for Q3 2026 reached $30.9 million, reflecting 14% year-over-year (YoY) growth and 1% sequential growth.
• Diagnostic products revenue was $16.8 million (up 16% YoY), driven by international HIV stabilization, HCV performance, and Sickle Scan growth.
• Sample Management Solutions (SMS) revenue was $12.5 million, growing 21% YoY and 20% sequentially due to key customer orders and the timing of commercial shipments.
• Gross margin expanded significantly, with GAAP gross margin rising to 45.2% (up 173 basis points) and non-GAAP gross margin reaching 45% (up 80 basis points) from prior year levels.
• Operating expenses saw material sequential improvement: R&D dropped $1.8 million to $7.6 million; G&A declined $2.4 million to $12 million due to reduced non-recurring legal/professional costs; Sales & Marketing remained flat at $6.6 million.
• GAAP operating loss was $13 million; non-GAAP operating loss was $10.2 million.
• Balance sheet strength includes zero debt and $148.2 million in cash and cash equivalents (note: transcript cites "$148.2 trillion" which is a transcription error for millions).
• Operating cash flow for Q3 was negative $10.9 million.

Guidance and Future Outlook:

• Q4 2026 revenue is projected between $30 million and $32 million, implying 12-20% YoY growth for the quarter.
• Full-year 2026 revenue guidance is set between $119.5 million and $121.5 million, representing 3.8% to 5.6% growth (midpoint 4.7%).
• Full-year 2027 revenue growth is expected to accelerate compared to 2026, with specific insights to be provided in the Q4 earnings call.
• Cash flow from operations break-even is revised to the second half of 2027, down from the beginning of the year, due to delayed timelines on the CT/NG molecular self-test and evolved order timing for Ebola and other growth opportunities.
• Gross margins for Q4 are expected to be similar to or slightly below Q3 levels, with long-term margin improvement driven by operational efficiencies and manufacturing absorption.

Business Segments and Product Lines:

• International Diagnostics: Strategy focuses on stabilization, localization, and diversification; achieved FDA EUA for OraQuick Ebola 2.0; launched local assembly in Uganda with expansion planned for Nigeria; Sickle Scan demand is growing in Africa supported by partnerships in Nairobi.
• U.S. Diagnostics: Strong growth driven by HCV, syphilis, and HIV testing; "Syndemic" testing strategy (HIV, HCV, Syphilis combined) continues to differentiate the portfolio.
• Sample Management Solutions: Commercial launch of Collipede DX Urine Collection Kit (FDA cleared June); initial sales are strong, with multiple customers evaluating self-collection workflows; partnership with Nucleoprecision chemistry enhancing the pipeline.
• CT/NG Molecular Self-Test: Withdrawn submission is being re-evaluated via a pre-submission process to align on the optimal regulatory path; R&D investment continues, including early HPV testing development in collaboration with global partners.

Market and Competitive Landscape:

• Ebola outbreak in DRC has surpassed 10,600 confirmed cases and 5,200 deaths; the company is positioned for "point-of-need" deployment in a high-transmission environment.
• International health security is shifting toward African-led, locally-manufactured solutions (Africa CDC focus), creating a need for companies with local assembly capabilities like OraSure's Uganda launch.
• Sickle cell disease awareness is driving demand for newborn screening in Africa (300,000-400,000 births annually); company is leveraging partnerships to expand Sickle Scan access.
• STI testing market is evolving toward convenient, private self-collection methods, presenting an opportunity for the Collipede DX platform.

Risks and Challenges:

• Regulatory timeline uncertainty for the CT/NG self-test resubmission; reliance on the pre-sub process could delay commercialization and revenue impact.
• Delayed cash flow break-even (shifted to H2 2027) due to the withdrawal of the CT/NG milestone and evolving timing of Ebola/other product adoption.
• International market volatility and complex, country-specific registration processes in Africa which are slower than historical models.
• Revenue mix fluctuations and order timing volatility in Sample Management and International segments, causing sequential revenue variability.

Management Commentary and Tone:

• Management tone is confident in the "return to growth" strategy, emphasizing disciplined cost reduction and gross margin expansion.
• CEO Kerry Eglinton-Manner highlighted the successful integration of Biomedomics and the strategic pivot to localized international capabilities.
• CFO Ken McGrath reinforced the commitment to cost discipline while maintaining R&D investment for future innovation.
• The company acknowledges the withdrawal of the CT/NG submission but expresses confidence in the product's performance and ability to navigate the regulatory landscape via alternative pathways.

Analyst Questions and Answers:

• CT/NG Resubmission: Management declined to specify a timeline, noting they are exploring various regulatory paths to minimize costs (e.g., avoiding milestone payments); R&D spend expected to remain similar to Q3 with potential fluctuations for HPV investments.
• Q4 Guidance Mix: Explained that Q3 SMS strength partially offset slower international timing, creating a "mix shift" where international volume is expected to return in Q4; Q4 revenue guidance implies flat sequential growth.
• EBOLA Contribution: No specific revenue contribution from Ebola or Collipede is quantified in the Q4 guidance yet; management emphasizes "initial orders" and early momentum but expects the major commercial catalyst to follow the Bridge Access Study results and local country registrations, likely before year-end.
• Cash Flow Trajectory: Break-even in H2 2027 is driven by three levers: gross margin expansion (170+ bps), sustained OPEX efficiency, and revenue growth acceleration from new products and core portfolio.

Other Key Points:

• Strategic partnership update: OraSure remains a minority investor in Onvera (formed by the combination of Safros and Hildred-backed Banks Health); existing strategic agreements with Salfros remain in place.
• Non-cash stock compensation was $2.3 million; depreciation and amortization was $2.2 million in Q3.
• The company is actively leveraging its manufacturing capabilities and partnerships to support the global response to the Ebola outbreak while maintaining focus on long-term value creation.